Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal ...
Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...
Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...
In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...
The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...
Singular Genomics (OMIC) announced key development milestones for its G4X Spatial Sequencer at the Advances in Genome Biology and Technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback